Continuing collaboration will utilize the capabilities of the Medidata Data Experience, fostering efficiency, fast-tracking research breakthroughs, and raising the standard of clinical trials

Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, and the NHMRC Clinical Trials Centre (CTC) at the University of Sydney have announced an expansion of their long-standing collaboration. Established in 2018, the relationship between Medidata and CTC has grown to include the Medidata Platform across major new studies.

Medidata enables the CTC to streamline its clinical trial operations by consolidating multiple data systems onto the industry proven unified platform, improving data management and expanding the center's research capabilities. The CTC is also using additional Medidata solutions to streamline trials across a broader range of research and increase to 30 concurrent studies. These connected workflows advance the Medidata Data Experience by accelerating data availability, generating actionable insights, and improving data quality.

"We have been utilizing Medidata for the past 6 years, in particular for studies that may feasibly contribute to regulatory submissions, and are impressed with Medidata's proactive approach to compliance with global data privacy and security regulations," said Professor Meg Jardine, director, NHMRC Clinical Trials Centre. "As a thriving academic Clinical Trials Centre, we are leaders in the development of adaptive and platform trials. We have built strong two-way relationships with Medidata to support our expert clinical data systems team in delivering stream-lined functionality in these complex and evolving trial settings."

"The CTC's contribution to advancing clinical research and care has led to better patient outcomes," said Edwin Ng, senior vice president and general manager, Asia-Pacific, Medidata. "By expanding our work together, we are not only fortifying the value of Medidata's unified platform, but also empowering the CTC to accelerate their research. We look forward to further supporting the CTC's mission and helping them drive continued innovation in Australian clinical trials."